Erythromycin Cydocarbonate improvement of clinical symptoms of mycoplasma pneumonia and analysis of immunoglobulin level changes and mechanism

Yingwei Bi,Hong Wang,Wei Wang,Shaojie Ma
DOI: https://doi.org/10.3760/cma.j.issn.1673-436X.2018.17.004
2018-01-01
Abstract:Objective Analysis of erythromycin Cydocarbonate improvement on clinical symptoms of mycoplasma pneumonia,immunoglobulin levels and mechanism.Methods 94 cases of mycoplasma pneumonia were selected from May 2014 to January 2017 in our hospital,according to random number method divided into control group and observation group.The patients in the control group were treatedwith erythromycin,and the patients in the observation group were treated with cyclopyrithromycin.The therapeutic effects of the two groups were analyzed,and the effects on the improvement of symptoms and the changes of immunoglobulin level were analyzed.Results The observation group of children with fever,cough,rales,X-ray improvement time and hospitalization time were shorter than the control group (P < 0.05).After treatment,the levels of hypersensitive C-reactive protein (hs-CRP),interleukin-8 (IL-8),interleukin-10 (IL-10),interferon-γ (IFN-γ),pulmonary surfactant associated protein (SP-A),soluble intercellular adhesion molecule 1 (sICAM-1) were all increased compared with those before treatment.The levels of serum inflammatory factor and serum immunoglobulin SP-A、sICAM-1 in the observation group were lower than those in the control group (P <0.05).Conclusions Erythromycin Cydocarbonate treatment of mycoplasma pneumonia can relieve inflammatory response,regulation of children with SP-A,the level of sICAM-1,improve the immune function of children with mycoplasma pneumonia,achieve the treatment purpose.
What problem does this paper attempt to address?